Telomir Pharmaceuticals Inc. (TELO) has regained compliance with Nasdaq Listing Rule 5620(a), stabilizing its listing status. An analyst has rated TELO as a Buy with a price target of $8.00, alleviating investor uncertainty.

NodeGuardian

2026-04-14 04:21:03

Abstract generation in progress

Telomir Pharmaceuticals Inc. (TELO) has announced it has regained compliance with Nasdaq Listing Rule 5620(a) following its 2025 Annual Meeting of Shareholders. This resolution stabilizes the company’s Nasdaq listing status and removes uncertainty for investors. An analyst has rated TELO stock a Buy with an $8.00 price target.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
116.14K Popularity
#
GateMarchTransparencyReport
41.26K Popularity
#
GoldmanSachsFilesBitcoinIncomeETF
775.33K Popularity
#
USBlocksStraitofHormuz
747.48K Popularity
#
WCTCTradingChallengeShare8MUSDT
508.38K Popularity

Sitemap

Telomir Pharmaceuticals Regains Nasdaq Listing Rule Compliance

Trending Topics

GatePreIPOsLaunchesWithSpaceX

GateMarchTransparencyReport

GoldmanSachsFilesBitcoinIncomeETF

USBlocksStraitofHormuz

WCTCTradingChallengeShare8MUSDT

Pin